NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IBIII ALK plus NSCLC

被引：0
|
作者：
Lee, J. M. [1 ]
Toloza, E. M. [2 ,3 ]
Pass, H. I. [4 ]
Johnson, B. E. [5 ]
Heymach, J. V. [6 ]
Sholl, L. [7 ]
Saqi, A. [8 ]
Travis, W. D. [9 ]
Wistuba, I. [6 ]
Lin, J. [10 ]
Kris, M. G. [9 ]
Spira, A. I. [11 ,12 ]
Shu, C. A. [8 ]
Saltos, A. N. [13 ]
Ding, B. [14 ]
Schulze, K. [14 ]
Zhu, Q. [14 ]
Ngiam, C. [14 ]
Bara, I. [14 ]
Chaft, J. E. [9 ]
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[3] Univ South Florida Hlth, Morsani Coll Med, Tampa, FL USA
[4] NYU Langone Med Ctr, New York, NY USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] MD Anderson Canc Ctr, Houston, TX USA
[7] Brigham & Womens Hosp, Boston, MA USA
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Univ Michigan, Med Sch, Ann Arbor, MI USA
[11] US Oncol Res, The Woodlands, TX USA
[12] Virginia Canc Specialists, Fairfax, VA USA
[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[14] Genentech Inc, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
alectinib; neoadjuvant; local-regional NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.01-06
引用
收藏
页码：S297 / S298
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Envafolimab Plus Platinum-based Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB NSCLC
    Zhang, H.
    Zhao, G.
    Gu, J.
    Ge, D.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S340 - S341
  • [42] Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK plus Non-Small-Cell Lung Cancer (NSCLC)
    Yang, James Chih-Hsin
    Ou, Sai-Hong
    De Petris, Luigi
    Gadgeel, Shirish
    Gandhi, Leena
    Kim, Dong-Wan
    Barlesi, Fabrice
    Govindan, Ramaswamy
    Dingemans, Anne-Marie
    Crino, Lucio
    Lena, Herve
    Popat, Sanjay
    Ahn, Jin Seok
    Dansin, Eric
    Golding, Sophie
    Bordogna, Walter
    Balas, Bogdana
    Morcos, Peter N.
    Zeaiter, Ali
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1170 - S1171
  • [43] Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK plus NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
    Camidge, D. Ross
    Sugawara, Shunichi
    Kondo, Masashi
    Kim, Hye Ryun
    Ahn, Myung-Ju
    Yang, James C. H.
    Han, Ji-Youn
    Hochmair, Maximilian J.
    Lee, Ki Hyeong
    Delmonte, Angelo
    Kudou, Kentarou
    Asato, Takayuki
    Hupf, Bradley
    Vranceanu, Florin
    Fram, Robert J.
    Ohe, Yuichiro
    Popat, Sanjay
    LUNG CANCER, 2025, 201
  • [44] Final Result of Phase I/II Study (AF-001JP) of Alectinib, a Selective CNS-Active ALK Inhibitor, in ALK plus NSCLC Patients (Pts)
    Nishio, M.
    Kiura, K.
    Seto, T.
    Nakagawa, K.
    Maemondo, M.
    Inoue, A.
    Hida, T.
    Yoshioka, H.
    Harada, M.
    Ohe, Y.
    Nogami, N.
    Murakami, H.
    Takeuchi, K.
    Inamura, S.
    Kuriki, H.
    Shimada, T.
    Tamura, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1757 - S1757
  • [45] A Phase IA Study of Ceritinib plus Trametinib in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: Preliminary Results
    Lara, M.
    Gubens, M.
    Bacaltos, B.
    Lim, S.
    Li, T.
    Gandara, D.
    Riess, J.
    Blakely, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1103 - S1103
  • [46] Neoadjuvant capecitabine (X) plus clocetaxel (T) for patients (pts) with locally advanced breast cancer (LABC): Preliminary safety and efficacy data
    Lybaert, W.
    Wildiers, H.
    Neven, P.
    Christaens, M.-R.
    Weltens, C.
    Drijkonngen, R.
    Van Ongeval, C.
    Van Steen, A.
    Paridaens, R.
    EJC SUPPLEMENTS, 2005, 3 (02): : 105 - 106
  • [47] A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
    Lemmon, Christopher A.
    Videtic, Gregory M. M.
    Murthy, Sudish
    Stephans, Kevin L.
    Shapiro, Marc
    Ahmad, Usman
    Raymond, Daniel
    Velcheti, Vamsidhar
    Bribriesco, Alejandro
    Jia, Xuefei
    Stevenson, James
    Pennell, Nathan A.
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (07):
  • [48] Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
    Leonetti, Alessandro
    Minari, Roberta
    Boni, Luca
    Gnetti, Letizia
    Verze, Michela
    Ventura, Luigi
    Musini, Luca
    Tognetto, Michele
    Tiseo, Marcello
    CLINICAL LUNG CANCER, 2021, 22 (05) : 473 - 477
  • [49] Efficacy and safety of adjuvant alectinib vs platinum-based chemotherapy (CT) in patients (pts) from Asia with resected, early-stage ALK plus non-small cell lung cancer (NSCLC): A sub analysis of ALINA
    Ahn, J. S.
    Wu, Y-L.
    Dziadziuszko, R.
    Barlesi, F.
    Nishio, M.
    Lee, D. H.
    Lee, J-S.
    Zhong, W-Z.
    Horinouchi, H.
    Mao, W.
    Lu, S.
    Wang, Q.
    Yang, C-T.
    Korphaisarn, K.
    Xu, T.
    Bu, L.
    Scalori, A.
    Petric, P.
    Redhead, K.
    Solomon, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1646 - S1647
  • [50] Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK plus ) non-small cell lung cancer (NSCLC) in a phase 1/2 trial
    Rosell, R.
    Gettinger, S. N.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S114 - S114
12345